Clinical trial Recruiting at 1 site Observational Ages Any age to 18

Understanding and managing growth issues and birth defects in fetuses and infants

Official title: Diagnosis and Management of Intrauterine Growth Restriction, Structural Anomalies and Chromosomal Anomalies: A Prospective Cohort Study

Run by Guangzhou Women and Children's Medical Center · NCT03398629 · Data updated 2026-11-12

This study is trying to gather information and samples from babies with growth issues or birth defects to see how these conditions develop and what can help improve their care.

Quick facts

Study typeObservational
AgesAny age to 18 Years
SexAll
Enrollment10000 (estimated)
SponsorGuangzhou Women and Children's Medical Center
Academic / other
Locations1 site (Guangzhou, Guangdong)
StatusRecruiting
StartedMay 1, 2019
Main results expectedMarch 1, 2038
Study endsMarch 1, 2038
Registry record updatedJune 4, 2019
Trial IDNCT03398629 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include pregnant women and neonates/infants diagnosed with IUGR or congenital anomalies at Guangzhou Women and Children's Medical Center.

Probably not a fit

Patients who are pregnant but do not agree to participate or deliver at other hospitals may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to create a comprehensive platform that collects clinical information and biological specimens from fetuses and infants diagnosed with intrauterine growth restriction (IUGR) or congenital anomalies. By following these cases from prenatal diagnosis through postnatal outcomes, the study seeks to explore the occurrences, progression, and clinical outcomes of these conditions. The research will also investigate potential factors, pathogenesis, and prognostic biomarkers associated with IUGR and congenital anomalies, ultimately aiming to improve diagnosis and treatment strategies. This large-sample prospective cohort study is designed to fill the gap in existing research by linking intrauterine and extrauterine data.

Why it matters

Potential benefit: If successful, this study could lead to improved diagnostic accuracy and treatment options for infants with growth restrictions and congenital anomalies.

How similar studies have gone: While there have been studies on screening for these conditions, this approach of linking intrauterine and extrauterine data is relatively novel and untested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

All pregnant women who present to Guangzhou Women and Children's Medical Center meeting one of the following prenatal diagnoses and neonates/infants who are diagnosed as one of the following anomalies will be invited to participate:

1. Intrauterine growth restriction (IUGR)
2. Structural anomaly
3. Chromosomal anomaly

Exclusion Criteria:

1. Pregnant women who don't agree to participate;
2. Pregnant women delivering babies at other hospitals.
3. Prenatally suspected anomalies that are not confirmed by postnatal diagnosis.

Where it's running

  • Guangzhou Women and Children's Medical Center
    Guangzhou, Guangdong, China
    Recruiting

Study contacts

  • Principal investigator: Wei Zhong, Master — Guangzhou Women and Children's Medical Center
  • Study coordinator: Wei Zhong, Master
  • Email: zhongwei@gwcmc.org
  • Phone: 020-38076288

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.